Fresh news on business and economy in Switzerland
Provided by AGP
AGP Picks
View all
Perspectify News
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
5 hours ago
Swiss banks hit with three-digit million lawsuit
Press releases
Publish your press release
2 hours ago
Refinery Catalysts Market worth $7.09 billion by 2030 at CAGR 4.0%, says MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL, May 04, 2026 (GLOBE NEWSWIRE) -- In terms of value, The Refinery Catalysts Market is projected to grow from USD 5.81 billion in 2025 to USD 7.09 billion by 2030, at a CAGR of 4.0% during the forecast period. as per the recent...
an hour ago
Logistics Automation Market Surges to $52.53 billion by 2029 | CAGR 8.4%
GlobeNewswire, Inc.
Delray Beach, FL, May 04, 2026 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the global Logistics Automation Market will increase from USD 35.14 billion in 2024 to USD 52.53 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%...
4 hours ago
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
GlobeNewswire, Inc.
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology...
9 hours ago
Delirium Market to Hit USD 522 Million by 2032 at 5.45% CAGR | Maximize Market Research
EIN Presswire
Delirium care is shifting from antipsychotics to AI diagnostics, biomarkers, and non-drug ICU protocols.
4 hours ago
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
GlobeNewswire, Inc.
ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered...
4 hours ago
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
GlobeNewswire, Inc.
PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations,...
Video Stories
Sign up for Business Daily Switzerland.
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
